

# Subject Index

- Acid phosphatase 202, 203, 206
- Adriamycin 207, 210–213
- Alkaline phosphatase 56–57, 202
- Aminoglutethimide 211
- Anandron 178, 180
- Androgen ablation methods 174–181
- Androgen action 174
- Androgen metabolism 67
- Androgen receptor (AR) 63, 71
  - and response to endocrine manipulation 65–70
    - salt-extractable 69
    - salt-resistant 70
- Androgen resistance syndromes 63
- Androgen sensitivity
  - histochemical indicators 71–72
  - potential biochemical markers 71
- Androgen stimulation 211
- Androstenedione 174
- Antiandrogens 177–179
- Asthenia 179
- Autopsy 17, 18, 108, 117, 201
  
- Basal cells 44, 48
- Basement membrane 48
- BB fraction of creatine kinase 203
- Bellweather radical prostatectomy series 136–137
- Benign prostatic hyperplasia 21–22, 85, 86, 87, 93, 94, 96, 107
- Benign prostatic hypertrophy 64, 73, 204
- Benign prostatic obstruction 108
- Biochemical investigation, factors limiting 64–65
- Biopsy results after interstitial radiotherapy 154–155
- Bladder tumors 88
- Bone alkaline phosphatase 204
- Bone metabolism 213
- Bone metastasis 201
- Bone radiography 201
  
- Brachytherapy 145–146
- Breast cancer 63
- Buserelin 177, 180
- t*-Butyl-6 serine-1-9 nonapeptide 180
  
- Chemohormonal therapy 191–192
- Chemotherapy 185–196, 203
  - adjunctive, coupled to hormonal therapy 181
  - adjuvant 187, 192
  - clinical trials 210–212
  - combination 189–191, 193
  - future approaches 192–193
  - general pessimism about 185
  - general situation 185–186
  - ideal approach to 187
  - patient selection 186
  - recent trials 189–192
  - response criteria 186–187
  - results in NPCP clinical trials 188
  - single agent 187
- Chloroethyl-cyclohexy-nitrosourea (CCNU) 190
- Cisplatin 211
- Clinical records 19
- Clinical trials 15–21, 197–219
  - chemotherapy 210–212
  - evaluation of anticancer agents 198
  - measurable disease 199–205
  - methodology of 198–199
  - patient selection 199
  - phase I 198
  - phase II 197–200, 207, 208, 212–213
  - phase III 207, 213
  - response assessment 205–207
  - safe and tolerated dose (MTD) 198
  - statistical considerations 208–209
- Clinically unrecognized tumors 107
- Combined gold seed implantation and external beam irradiation 147–148
  - results of treatment 153–154
  - selection of patients and techniques 150

- Combined iridium implantation and external beam irradiation 148
  - selection of patients and techniques 150–151
- Complete remission 205
- Computed tomography. *See* CT scanning
- Cost-effectiveness 26
- Creatinine kinase 202
- CT scanning 88–91, 131, 163–164, 200, 203
- Cure 3
- Cyclophosphamide 188–192, 211–213
- Cyproterone acetate 178, 180
- CYTADREN 211
- Cytochrome P450 179
- Cytometric systems 47
- Cytoplasmic contents, heterogeneity of 43–44
- Cytosol androgen receptor 65–67
  
- Data interpretation 2–5
- Data quality 2
- Deaths 8, 10
- Dehydroepiandrosterone 174
- 17-20 Desmolase 179
- DFMO 213
- DHT 67, 68, 71, 73
- Diagnosis 12, 13, 19, 25
- Diarrhea 178
- Dietary factors 23–24
- Diethylstilbestrol (DES) 175, 176, 180–182, 188
- Diethylstilbestrol diphosphate 191
- Dihydrotestosterone (DHT) 65, 67–68, 71–73, 75, 177, 199
- Doxorubicin 189–191, 211
- Drug therapies 176
- DU-145 101
- Duration determination 3
  
- Early detection 24–26
- Echopenic prostatic cancer 87
- Emcyt 188, 189
- Endocrine manipulation 135, 185
- Endocrine therapy, 63, 134
- Endometrial cancer 63
- Enzyme-linked immunosorbent assay (ELISA) 55
- EORTC 176, 178, 211
- Epidemiology 1–28
- Erectile potency 133, 140–141, 166
- Estramustine 176
- Estrogen 63, 72–75
- Estrogen receptor 71, 73–74
- Estrogen therapy 175–176
- Ethnic differences 22–23
- Etiology 21–24
- Extended lymph node dissection 123
- External beam radiotherapy 147, 149, 159–172
  - first principles 159
  - lymph node metastases 169–171
  - selection of patients and techniques 150–151
  - treatment sequelae 165–166
  - treatment technique 163–165
- False-negative frozen sections 124
- Flare phenomenon 201
- 5-Fluorouracil 188–191, 210, 211, 213
- Fluoxymesterone 212
- Flushing 178
- Flutamide 178, 180, 181, 183
- Frequency 7
- Frozen section
  - examination of pelvic nodes 123–125
  - sensitivity of 124
  
- Gaeta system 30
- Gamma irradiation 150
- Genetic factors 23
- Geographic differences 22–23
- Gleason system 30–34, 40–42, 121, 122
  - reliability 33–34
  - reproducibility 32
- Glucocorticoid insufficiency 179
- Glucocorticoid receptors 63
- Grade I 29, 30, 39
- Grade II 29, 30, 39, 40
- Grade III 29, 30, 39, 40
- Grade IV 29, 30
- Grading systems 29–47
  - alternative 34–41
  - future perspectives 44–45
  - Gaeta system 30
  - Gleason system 31–34, 41, 42
  - heterogeneity of cytoplasmic contents 43–44
  - Mayo system 30
  - Mostofi system 31–32
  - NPCP recommendations 32
  - NPCP task force 30–32
  - pathologic prognostication 41–44
  - reliability 29
  - reproducibility 29
- Gynecomastia 178
  
- Halotestin 212
- Hepatomegaly 205
- Hepatotoxicity 179
- Heterogeneity of cytoplasmic contents 43–44
- Hopkins radical prostatectomy series 136–137
- Hormonal levels 24
- Hormonal therapy 173–183
  - coupled to adjunctive chemotherapy 181
  - history of 173
  - optimal time for initiation of therapy 181–183
  - sensitivity to 199
  - success and failure of 179–180
  - survival patterns 182
- Hormone receptors 63–81
- Hormone-refractory prostatic cancer 185, 189
- Hormone-resistant prostatic cancer 209
- $\alpha_2$ -HS glycoprotein 205
- 17-Hydroxylase 179
- Hydroxyproline 202, 204
- 17 $\beta$ -Hydroxysteroid oxidoreductase 71

- 3 $\alpha$  ( $\beta$ )-Hydroxysteroid oxidoreductase 71  
 Hypochoic lesion 86  
 Hypogastric nodes 119
- Iliac nodes 119  
 Imaging techniques 83–98, 163  
 Immunodiagnostic scanning 101–102  
 Impotence 130, 174  
 Incidence 3, 5–11  
   age 9–10  
   age-standardized 6, 7  
   cumulative 6, 7, 9  
   positive nodes 120–121  
   time trends in 10–11  
   within-country 7  
   world 5  
 Incidental tumors 107  
 Incomplete resection 159  
 International Agency for Research on Cancer 2  
 International Classification of Diseases 2  
 Interstitial radiotherapy 145–158  
   biopsy results after 154–155  
   combined gold seed implantation and external  
     beam irradiation 147–148  
     results of treatment 153–154  
     selection of patients and techniques 150  
   combined iridium implantation and external  
     beam irradiation 148  
   complications 151  
   contemporary experience with 145  
   early techniques 145  
   history 145  
   radioactive iodine implantation 146–147  
     results of treatment 152  
     selection of patients and techniques 149  
   results of treatment 152  
   selection of patients and techniques 148–151  
   treatment techniques 146–148  
 Isoenzyme profiles 57
- Kaplan-Meier plot 170  
 Ketoconazole 179
- Lactic dehydrogenase (LDH) isoenzymes IV  
   and V 57  
 Latent stage 24–25  
 Latent tumor 108  
 Leuprolide 180  
 Libido loss 174  
 Lifetime risk 8  
 Limited node dissection 122  
 Localized adenocarcinoma of the prostate,  
   management of 129–144  
 Lomustine 190, 213  
 Lupron 176, 177  
 Luteinizing hormone 199  
 Luteinizing hormone releasing hormone  
   (LHRH) 176–177, 179–181, 183
- Lymph node dissection 121–123  
 Lymph node metastases 111  
   external beam radiotherapy 169–171  
 Lymphadenectomy 121, 123  
 Lymphadenopathy 170  
 Lymphangiography 99–101, 131, 203  
 Lymphatic channels 117–119  
 Lymphatic drainage 119–120  
 Lymphocytic leukemia 63
- M** category 113  
 M<sub>0</sub> category 113  
 M<sub>1</sub> category 113  
 M<sub>x</sub> category 113  
 M-MAB 102  
 Magnetic resonance imaging (MRI) 91–98, 200  
 Magnetic resonance spectroscopy (MRS) 98–99  
 Mayo system 30  
 Medically indigent patients 18  
 Medroxyprogesterone acetate (MPA) 178  
 Megace 178  
 Megestrol 178  
 Memorial Sloan-Kettering Cancer Center  
   (MSKCC) 111, 145, 151, 199, 200, 203,  
   210  
 Metastatic disease 21, 25, 107, 112, 131,  
   173–183, 186, 188, 199  
 Methotrexate 181, 188, 189, 211  
 Methyltrienolone 66  
 MGBG 213  
 MHG7 102  
 Minor response 205, 207  
 Mitomycin-C 189, 211  
 Modified node dissection 122  
 Monoclonal antibodies 101–102, 213  
 Monoclonal antibody-defined antigens 58  
 Mortality and mortality data, 2, 3, 9–12  
 Mostofi system 31–32
- N** category 113  
 N<sub>0</sub> category 113  
 N<sub>1</sub> category 113  
 N<sub>2</sub> category 113  
 N<sub>3</sub> category 113  
 N<sub>4</sub> category 113  
 N<sub>x</sub> category 113  
 Nafarelin 177  
 $\alpha$ -Naphthyl phosphate 202  
 National Prostatic Cancer Project (NPCP) 30,  
   32–34, 41, 42, 187, 191–193, 202, 209,  
   210  
 National Prostatic Cancer Treatment Group  
   (NPCTG) 181, 187  
 Natural history, variability of 47  
 Negative nodes 123  
 Nitrogen mustard 176  
 Nonsteroidal antiandrogens 178  
 Northern California Oncology Group (NCOG)  
   200, 210

- Nuclear anaplasia, grades of 39  
 Nuclear androgen receptor 69–70  
 Nuclear roundness, 43, 199
- Objective regression** 206, 207  
**Objective response** 206  
**Obturator nodes**, 100, 119  
**Occult tumor** 107  
**Orchiectomy** 134, 174, 180, 181, 188, 191, 192  
**Osteocalcin** 202, 204  
**Osteonectin** 205
- P* value 209  
**Para-aortic nodes** 119  
**Paraneoplastic syndromes** 107  
**Partial remission** 205  
**Partial remission criteria** 206  
**Pathologic prognostication** 41–44  
**Pathologic studies** 15–21  
**Pattern-1** 31  
**Pattern-2** 31  
**Pattern-3** 31  
**Pattern-4** 31  
**Pattern-5** 31  
**PC-3** 101  
**Pelvic lymph node dissection** 125–126  
**Pelvic lymph node metastases** 131  
**Pelvic lymph nodes** 112, 117–128, 169  
**Pelvic lymphadenectomy** 138  
**Pelvic lymphadenopathy** 131  
**Pelvic node metastasis** 120  
**Pelvic nodes, frozen section examination of**  
     123–125  
**Physical examination** 25, 47, 200, 203  
**Poisson distribution** 159  
**Polyamine inhibitors** 213  
**Polypeptide hormones** 75–76  
**Positive lymph nodes** 154  
**Positive nodes** 123, 125  
     incidence of 120–121  
**Positive tissue margins** 141–142  
**Positron emission tomography (PET)** 102  
**Prevalence** 3  
**Progestational agents** 178  
**17OH-Progesterone** 179  
**Progesterone receptor** 74–75  
**Progesterin** 63  
**Prognostic factors** 199  
**Prognostic systems** 40  
**Progression (PROG)** 205  
**Prolactin receptors** 75–76  
**Prostate-specific acid phosphatase (PSAP)** 72  
**Prostate-specific antigen** 47, 54–56, 202–204  
     biochemical characteristics 54–55  
     immunoassays 55  
     immunochemical characteristics 54–55  
     simultaneous immunoassays with prostatic  
     acid phosphatase 55–56  
**Prostatectomy** 20, 108, 123, 125, 150  
**Prostatic acid phosphatase** 47, 48–54, 204  
     biochemical characteristics 49  
     clinical application 51–54  
     immunoassay 52  
     immunochemical characteristics 49  
     immunohistology 53  
     immunologic assays 54  
     monitoring 53  
     role as tumor marker 48  
     screening 53  
     sensitivity 51  
     serum level 50  
         enzymatic methods 50  
         immunologic methods 50  
         normal values 51  
     simultaneous immunoassays with  
     prostate-specific antigen 55–56  
     specificity 51  
     vs stage and grade 51–53  
**Prostatic antigen (PA)** 101  
**Prostatism** 25  
**Pulmonary disease** 201
- Quality of life** 213
- Radiation cystitis** 133  
**Radiation failure** 159  
**Radiation proctitis** 133  
**Radiation sources** 133  
**Radiation therapy** 129–131  
     long-term efficacy of 136  
     persistence of cancer cells in patient presumed  
     to be cured by 134  
     problems with 133  
     selection criteria 131–132  
     treatment failures after 133  
**Radical prostatectomy** 19, 136, 148  
     complications of 139–142  
**Radical retropubic prostatectomy** 140–141  
**Radioactive iodine implantation** 146–147  
     results of treatment 152  
**Radioactive sources** 135, 145  
**Radioactive treatment, survival after** 135–136  
**Radioimmunoassay** 202  
**Radioisotopic bone scan** 132  
**Radionuclide bone scanning** 201  
**Radioresistance** 149  
**Radiotherapy**  
     vs surgery 166  
     see also Interstitial radiotherapy  
**Rat ventral prostate** 66  
**Receptor activity** 67  
**Rectal examination** 47, 132  
**5 $\alpha$ -Reductase** 71  
**Registration data** 14–21  
**Registrations** 8, 10  
**Relative survival rate (RSR)** 11  
**Response criteria** 205–207  
**Risk-benefit ratio** 159, 187  
**RU23908** 180

- Salt-extractable androgen receptor 69
- Salt-resistant androgen receptor 70
- Screening 25
- Sensitivity of frozen section 124
- Serum alkaline phosphatase 47
- Serum prostatic acid phosphatase 132
- Serum ribonuclease levels 57
- Sex hormone binding globulin (SHBG) 65, 66
- Sexual function 133
- Sexual impotence 130
- Sodium dodecylsulfate-polyacrylamide gel electrophoresis (SDS-PAGE) 55
- Sonography 200
- Southwest Oncology Group (SWOG) 190
- Spironolactone 179
- Stabilization (STAB) 205, 207
- Stage A (I) 107–110
  - subdivisions of 109
  - survival patterns 168–169
- Stage A<sub>1</sub> 108–110, 168, 171
- Stage A<sub>2</sub> 108–110, 131, 141, 168, 171
- Stage B (II) 110–111, 131, 170
  - subdivisions of 110
  - survival patterns 160–163
- Stage B<sub>1</sub> 108, 110, 124, 141, 160, 171
- Stage B<sub>in</sub> 111
- Stage B<sub>2</sub> 110, 171
- Stage C (III) 111, 134, 171, 182, 197
  - survival patterns 166–168
- Stage C<sub>1</sub> 111
- Stage C<sub>2</sub> 111
- Stage C<sub>3</sub> 111
- Stage D (IV) 111–112, 171, 179, 182, 197
- Stage D<sub>0</sub> 112
- Stage D<sub>1</sub> 112, 183
- Stage D<sub>2</sub> 112, 183
- Stage D<sub>3</sub> 112
- Stage T<sub>1</sub> (B<sub>1</sub>) 160
- Stage T<sub>2</sub> (B<sub>2</sub>) 160
- Staging systems 121–122
  - update in 107–115
- Steroidal antiandrogens 178
- Steroidogenesis inhibitors 179
- Stilphostrol 191
- Suprapubic prostatectomy 86
- Surgery
  - failure of 159
  - survival after 136–139
  - vs radiotherapy 166
- Survival 11–21
  - after surgery 136–139
  - apparent improvement in 13
  - by age 13–14
  - cumulative 11
- Survival data 4, 5, 20
- Survival patterns
  - after X-irradiation 160
  - hormonal therapy 182
  - stage A tumors 168–169
  - stage B tumors 160–163
  - stage C tumors 166–168
- Survival rates 12, 14–18, 21
  - international comparisons 14
- T category 112, 113
- T<sub>0</sub> category 112, 113
- T<sub>1</sub> category 112
- T<sub>1a</sub> category 113
- T<sub>1b</sub> category 113
- T<sub>2</sub> category 113
- T<sub>2a</sub> category 113
- T<sub>2b</sub> category 113
- T<sub>3</sub> category 113
- T<sub>3a</sub> category 113
- T<sub>3b</sub> category 113
- T<sub>4</sub> category 113
- T<sub>x</sub> category 112, 113
- TEBG 174, 175
- Testosterone 174, 177, 199
- Tissue acquisition 64–65
- Tissue heterogeneity 65
- Tissue margins 141–142
- TNM (tumor, node, metastasis) system 112–113
- Transabdominal (TAU) ultrasound 83, 85, 88
- Transrectal sonography 83
- Transrectal ultrasound 83–88
- Transurethral resection (TUR) 64
- Transurethral resection of the prostate (TURP) 149, 150
- Transurethral ultrasound 83, 88
- Treatment effectiveness 25
- Tumor activity measures 213
- Tumor markers 47–62, 202, 205
  - definition 47
  - examples of 47
  - summary and perspectives 59
  - see also under specific markers
- TURP-27 101
- Type I basal cells 44
- Type II basal cells 44
- Ultrasonography 83–88, 200
- Ultrastructure features 44
- Urinary hydroxyproline 57
- Urinary incontinence 139–140
- Urinary prostatic cancer antigen 58
- Urinary retention 25
- Urine hydroxyproline 47
- Uro-Oncology Research Group (UORG) 137–138
- Veterans Administration Cooperative Urological Research Group (VACURG) 31, 173, 182
- World Health Organization 2, 35
- X-irradiation, survival pattern after 160
- Zoladex 177